Timothy Alan Driscoll

Dr. Driscoll participates in multi-institutional studies for the treatment of high risk neuroblastoma patients using high dose chemotherapy with stem cell transplant and the development of new therapies for high risk neuroblastoma patients.

Current Appointments & Affiliations

Associate Professor of Pediatrics · 2024 - Present Pediatrics, Transplant and Cellular Therapy, Pediatrics

Recent Publications

Newborn Screening for Hurler Syndrome Facilitates Early Transplant and Good Outcomes.

Journal Article Pediatr Neurol · February 2025 BACKGROUND: Hematopoietic cell transplantation (HCT) is the standard of care treatment for children with Hurler syndrome (HS). This study describes the impact of newborn screening (NBS) on HCT outcomes for these patients. METHODS: Retrospective study of HS ... Full text Link to item Cite

Safety and feasibility of umbilical cord blood transplantation in children with neuronal ceroid lipofuscinosis: a retrospective study.

Journal Article Stem Cells Transl Med · January 17, 2025 Ceroid lipofuscinosis neuronal (CLN) encompasses rare inherited neurodegenerative disorders that present in childhood with clinical features including epilepsy, psychomotor delay, progressive vision loss, and premature death. Published experience utilizing ... Full text Link to item Cite

No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.

Journal Article Bone Marrow Transplant · December 2023 Full text Link to item Cite

View All Publications

Recent Grants

A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Subjects

Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2020 - 2024

A multicenter study of apheresis collection of peripheral blood mononuclear (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2020

Acid Sphingomyelinase Activation in Apoptosis

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 2002

View All Grants

Education, Training & Certifications

Ohio State University · 1990 M.D.